Amgen 2004 Annual Report Download - page 12

Download and view the complete annual report

Please find page 12 of the 2004 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 38

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38

Selected Amgen products
and product candidates
Infl ammation
Molecule Disease/condition
AMG 009 Asthma
AMG 108 Osteoarthritis
AMG 162 Rheumatoid arthritis
AMG 317 Asthma
AMG 623 Systemic lupus erythematosus
AMG 714 Rheumatoid arthritis
ENBREL®Rheumatoid arthritis
(etanercept)
ENBREL® Juvenile rheumatoid arthritis
ENBREL® Ankylosing spondylitis
(arthritis of the spine)
ENBREL® Psoriatic arthritis
ENBREL® Psoriasis
Kineret®Rheumatoid arthritis
(anakinra)
Kineret® Osteoarthritis
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Moving molecules from laboratory to patients involves years of detailed
investigation and rigorous testing. Clinical development requires enormous
investments in time and resources. It begins with preclinical testing and
proceeds through a series of human clinical trials that establish dosage levels,
test for effi cacy and side effects, and, depending on the molecule, may
ultimately seek to measure long-term patient outcomes.
Oncology
Molecule Disease/condition
AMG 102 Cancer
AMG 114 Chemotherapy-induced anemia
AMG 162 Bone metastases
(cancer spread to bone)
AMG 162 Bone loss induced by hormone
ablation therapy for breast
cancer or prostate cancer
AMG 386 Cancer
AMG 531 Immune thrombocytopenic
purpura (an autoimmune
bleeding disorder)
AMG 706 Cancer
AMG 951 Cancer
Aranesp®Chemotherapy-induced anemia
(darbepoetin alfa)
NEUPOGEN®Neutropenia
(Filgrastim) (multiple indications)
Neulasta® Chemotherapy-induced
(pegfi lgrastim) neutropenia
Panitumumab Colorectal cancer
Kepivance™ Severe oral mucositis associated
(palifermin) with hematologic transplant
Kepivance™ Oral mucositis associated
with radiation therapy and
chemotherapy for solid tumors
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Amgen 2004 Annual Report page 10